BPC-157 + TB-500
Peptide Stack · Combination ConceptSoft-tissue repair and recovery research
What Is This Combination?
ERP catalog context: BPC-157 10 mg + TB-500 10 mg -- total 20 mg
A two-component pairing commonly discussed in soft-tissue repair and recovery research, combining BPC-157's preclinical tissue-repair and vascular research with TB-500's actin-binding, cell-migration research -- component-level evidence only, with no controlled trial of the exact pairing.
The Concept
BPC-157 and TB-500 are commonly paired because their component-level research is discussed around different aspects of tissue repair and remodeling. That complementary rationale does not demonstrate that the combined formulation is more effective than either component alone.
Meet the Components
BPC-157
10 mgtissue-repair and vascular signaling arm
BPC-157 is studied in preclinical models for effects on angiogenesis, tendon and ligament healing, and gastrointestinal mucosal repair, providing a distinct repair-biology rationale from TB-500's actin-binding, cell-migration research.
Evidence base is preclinical (animal/cell) and does not establish human therapeutic efficacy. See the standalone BPC-157 page for its full evidence summary.
Preclinical evidence only
View BPC-157research profile →TB-500
10 mgdistinct cell-migration and remodeling signaling arm
As used on this page, TB-500 refers specifically to the short LKKTETQ fragment derived from thymosin beta-4, not the full-length 43-amino-acid protein. Its research is discussed in relation to actin binding, cell migration, and tissue-remodeling biology, distinct from BPC-157's own preclinical repair pathways.
No FDA-approved TB-500 product exists and FDA reports no identified human exposure data for the exact fragment; full-length thymosin beta-4 or RGN-259 human data cannot be transferred to TB-500. See the standalone TB-500 page for its full identity and evidence boundary.
No established human evidence
View TB-500research profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- soft-tissue repair biology
- tendon/ligament research
- wound/remodeling biology
- post-injury recovery research
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- nagging tendon or soft-tissue complaints(editorial-summary)
- training recovery discussions(editorial-summary)
- strain and injury recovery discussions(editorial-summary)
- joint and soft-tissue recovery discussion(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
No controlled exact-combination clinical efficacy evidence exists.Safety Consideration
TB-500 as sold is a short fragment distinct from full-length thymosin beta-4; findings for the full-length protein cannot be assumed to apply.Safety Consideration
Long-term systemic safety of either component, alone or combined, has not been established in controlled human research.Safety Consideration
Manipulating angiogenic and tissue-remodeling signaling carries theoretical risks that have not been directly studied for this pairing.Safety Consideration
A fixed-ratio blend makes it impossible to attribute any observed effect to one component over the other.Safety Consideration
Exact formulation stability and compatibility of a combined vial should not be assumed just because it is sold as one product.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- BPC-157 and TB-500 have different, independently developing evidence bases, so evaluating them together makes it harder to track what is actually known about each.
- Introducing one component at a time makes causal attribution of any observed effect or side effect meaningfully cleaner.
- The commonly sold 1:1 mass ratio (10 mg + 10 mg) is a supplier convention, not a ratio derived from any pharmacologic optimization study.
- Administering components separately allows either one to be stopped or held on its own without discontinuing the other.
Favoring the Fixed-Ratio Blend
- A fixed blend reduces the handling complexity of managing two separate vials and schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: No controlled or observational human trial of the exact BPC-157 + TB-500 combination was located. What exists is separate preclinical research on each component individually.
Limitations: Component-level preclinical findings do not establish the combined formulation's safety, efficacy, compatibility, or an evidence-derived mixing ratio.
Component evidence: Evidence strength varies by component -- see each component's own standalone page for its full evidence summary; this page does not restate or re-grade that evidence.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
BPC-157
BPC-157 is an experimental 15-amino-acid peptide promoted for repair and gastrointestinal uses. Published human evidence consists of two tiny uncontrolled pilots and one retrospective private-clinic report; most mechanistic support remains preclinical. FDA has identified significant product-characterization, impurity, aggregation, immunogenicity, and long-term safety uncertainties.
View research profile →TB-500
TB-500 is marketed as the short thymosin-beta-4 fragment LKKTETQ and is not the same molecule as full-length 43-amino-acid thymosin beta-4. FDA reports no identified human exposure data for drug products containing the exact fragment. Human studies of full-length thymosin beta-4 and RGN-259 are related biological context only and do not establish TB-500 efficacy, safety, pharmacokinetics, or dosing.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.